TEVA - Company ID 0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported revenue of $17.26B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $17.26B | +4.3% |
| FY 2024 | $16.54B | +4.4% |
| FY 2023 | $15.85B | +6.2% |
| FY 2022 | $14.93B | -6.0% |
| FY 2021 | $15.88B | -4.7% |
| FY 2020 | $16.66B | -1.4% |
| FY 2019 | $16.89B | -7.6% |
| FY 2018 | $18.27B | -16.4% |
| FY 2017 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported revenue of $17.26B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue declined from $18.31B to $17.26B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $21.85B |
| -0.2% |
| FY 2016 | $21.90B | +11.5% |
| FY 2015 | $19.65B | -3.1% |
| FY 2014 | $20.27B | -0.2% |
| FY 2013 | $20.31B | -0.0% |
| FY 2012 | $20.32B | +10.9% |
| FY 2011 | $18.31B | - |